ERBB2 and breast cancer: For instance, second-generation CAR-NK-92 cells co-expressing anti-HER2 and soluble PD-1 significantly increased NK cell and T cell infiltration and effector molecule release, enhancing immunological antitumour efficacy in PD-L1+Her2+ breast cancer cells (165).